Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • PH-10: Phase II started

    Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn. Product: PH-10 Business: Autoimmune Molecular target: NA Description: Topical aqueous hydrogel formulation of rose bengal disodium Indication: Treat mild…

    Published on 3/23/2015
  • PQ912: Phase IIa started

    Probiodrug AG (Euronext:PBD), Halle/Saale, Germany Product: PQ912 Business: Neurology Molecular target: Glutaminyl cyclase (QC) Description: Glutaminyl cyclase (QC) inhibitor Indication: Treat Alzheimers disease (AD) …

    Published on 3/23/2015
  • PRTX-100: Phase I/II started

    Protalex Inc. (OTCBB:PRTX), New Hope, Pa. Product: PRTX-100 Business: Autoimmune Molecular target: Not available Description: Purified form of staphylococcal protein A Indication: Treat rheumatoid arthritis (RA) …

    Published on 3/23/2015
  • PT20: Completed Phase IIb enrollment

    Phosphate Therapeutics Ltd., Newcastle, U.K. Shield Therapeutics AG, Wollerau, Switzerland Product: PT20 Business: Endocrine/Metabolic Molecular target: NA Description: Iron-based phosphate binder Indication: Treat …

    Published on 3/23/2015
  • PV-10: Completed Phase I enrollment

    Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn. Product: PV-10 Business: Cancer Molecular target: Not available Description: Sterile injection containing 10% rose bengal disodium Indication: Treat …

    Published on 3/23/2015
  • RVSV-EBOV: Phase III started

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: RVSV-EBOV, VSV-ZEBOV, VSV-EBOV Business: Infectious Molecular target: NA Description: Recombinant vesicular…

    Published on 3/23/2015
  • SEA-CD40: Phase I started

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: SEA-CD40 Business: Cancer Molecular target: CD40 Description: Non-fucosylated antibody targeting CD40 Indication: Treat solid tumors Endpoint: Safety and …

    Published on 3/23/2015
  • Single-Dose Sufentanil NanoTab: Phase III started

    AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), Redwood City, Calif. Product: Single-Dose Sufentanil NanoTab (ARX-04) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Sublingual formulation of …

    Published on 3/23/2015
  • Toraymyxin: Phase III ongoing

    Spectral Medical Inc. (TSX:EDT; OTCQX:EDTXF), Toronto, Ontario Product: Toraymyxin (polymyxin B immobilized fiber column) Business: Infectious Molecular target: NA Description: Hemoperfusion absorption column made of …

    Published on 3/23/2015
  • Varlilumab: Phase I/II started

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: Varlilumab (CDX-1127) Business: Cancer Molecular target: CD27 Description: Human mAb targeting CD27 Indication: Treat advanced refractory solid tumors …

    Published on 3/23/2015
  • Velusetrag: Phase IIb started

    Alfa Wassermann S.p.A., Bologna, Italy Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: Velusetrag (TD-5108) Business: Gastrointestinal Molecular target: Serotonin (5-HT4) receptor …

    Published on 3/23/2015
  • Vigil vaccine: Phase III started

    Gradalis Inc., Dallas, Texas Product: Vigil vaccine (formerly FANG vaccine) Business: Cancer Molecular target: Transforming growth factor (TGF) beta 1 (TGFB1); Transforming growth factor (TGF) beta 2 (TGFB2) Description…

    Published on 3/23/2015
  • VT-1161: Phase IIb started

    Viamet Pharmaceuticals Inc., Durham, N.C. Product: VT-1161 Business: Infectious Molecular target: Cytochrome P450 C-14 alpha demethylase (CYP51) Description: Oral small molecule inhibitor of fungal cytochrome P450 C-14 …

    Published on 3/23/2015
  • Apatorsen: Completed Phase II enrollment

    Isis Pharmaceuticals Inc.(NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc.(NASDAQ:OGXI), Bothell, Wash. Product: Apatorsen (OGX-427) Business: Cancer Molecular target: Heat shock protein 27 (Hsp27) …

    Published on 3/16/2015
  • Aramchol arachidyl amino cholanoic acid: Phase IIb started

    Galmed Pharmaceuticals Ltd.(NASDAQ:GLMD), Tel Aviv, Israel Product: Aramchol arachidyl amino cholanoic acid Business: Hepatic Molecular target: Stearoyl-CoA desaturase-1 (SCD1) Description: Synthetic conjugate of cholic…

    Published on 3/16/2015
  • AV-101: Phase II start

    VistaGen Therapeutics Inc.(OTCQB:VSTA), South San Francisco, Calif. Product: AV-101 (L-4-chlorokynurenine, 4-CI-KYN) Business: Neurology Molecular target: NMDA receptor Description: NMDA receptor antagonist Indication: …

    Published on 3/16/2015
  • CRS-207: Phase II started

    Aduro Biotech Inc., Berkeley, Calif. Product: CRS-207 Business: Cancer Molecular target: NA Description: Live attenuated strain of Listeria monocytogenes that expresses human mesothelin Indication: Treat pancreatic …

    Published on 3/16/2015
  • Glycopyrrolate bromide: Phase III started

    Sumitomo Dainippon Pharma Co. Ltd.(Tokyo:4506), Osaka, Japan Product: Glycopyrrolate bromide (SUN-101) (formerly EP-101) Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled formulation of …

    Published on 3/16/2015
  • GVAX Pancreas cancer vaccine: Phase II started

    Aduro Biotech Inc., Berkeley, Calif. Product: GVAX Pancreas cancer vaccine Business: Cancer Molecular target: NA Description: Allogeneic cancer vaccine engineered to secrete GM-CSF Indication: Treat pancreatic cancer …

    Published on 3/16/2015
  • Nalbuphine ER: Phase II/III started

    Endo International plc(NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa …

    Published on 3/16/2015
  • Oral neratinib: Phase II started

    Puma Biotechnology Inc.(NYSE:PBYI), Los Angeles, Calif. Pfizer Inc.(NYSE:PFE), New York, N.Y. Product: Oral neratinib (HKI-272, PB272) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (HER1)…

    Published on 3/16/2015
  • PEG-P-INF alfa-2b: Completed Phase III enrollment

    AOP Orphan Pharmaceuticals AG, Vienna, Austria PharmaEssentia Corp.(GreTai-E:6446), Taipei, Taiwan Product: PEG-P-INF alfa-2b, Ropeginterferon alfa 2b (AOP2014, P1101) Business: Hematology Molecular target: NA …

    Published on 3/16/2015
  • TRV027: Phase IIb ongoing

    Trevena Inc.(NASDAQ:TRVN), King of Prussia, Pa. Product: TRV027 (formerly TRV120027) Business: Cardiovascular Molecular target: Angiotensin II type 1 (AT1) receptor (AGTR1) Description: Dual-acting ligand that inhibits …

    Published on 3/16/2015
  • Vesigenurtacel-L: Phase I/II amended

    Heat Biologics Inc.(NASDAQ:HTBX), Chapel Hill, N.C. Product: Vesigenurtacel-L (HS-410) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Bladder cancer cell line …

    Published on 3/16/2015
  • Zmapp: Phase I/II started

    Defyrus Inc., Toronto, Ontario Mapp Biopharmaceutical Inc., San Diego, Calif. Product: Zmapp Business: Infectious Molecular target: NA Description: Combination of 3 mAbs targeting Ebola glycoproteins GP1 and GP2 …

    Published on 3/16/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993